Welcome to our dedicated page for TNF Pharmaceuticals SEC filings (Ticker: TNFA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TNFA SEC filings page on Stock Titan provides access to the regulatory history of TNF Pharmaceuticals, Inc., the company that later became Q/C Technologies, Inc. and now trades on Nasdaq under the ticker QCLS. These filings document key corporate events, financing transactions and the formal name and ticker symbol change that marked the company’s shift from a clinical stage biopharmaceutical focus toward quantum-class photonic computing and blockchain infrastructure.
Among the notable documents is an 8-K filed on September 26, 2025, which reports the filing of a Certificate of Amendment to change the corporate name from TNF Pharmaceuticals, Inc. to Q/C Technologies, Inc. and confirms that the company’s common stock ceased trading under TNFA and began trading under QCLS on the Nasdaq Stock Market. Other 8-K and 8-K/A filings describe a Securities Purchase Agreement for a private placement of Series H convertible preferred stock and warrants, the creation of Series I convertible preferred stock in connection with the acquisition of LPU Holdings LLC, and amendments to existing Series F and Series F-1 preferred stock designations.
Filings also include a Form 12b-25 (NT 10-Q), in which the company explains that it was unable to file its Quarterly Report on Form 10-Q for the six months ended June 30, 2025, within the prescribed time period without unreasonable effort or expense and anticipated filing within the allowed extension period. Together, these documents give insight into the company’s capital structure, preferred stock terms, acquisition agreements, licensing arrangements with LightSolver Ltd., and steps taken to manage its SEC reporting obligations.
On Stock Titan, users can review these TNFA filings alongside AI-powered summaries designed to clarify complex sections of 8-Ks, preferred stock designations and related agreements. Real-time updates from EDGAR ensure that new or amended filings tied to the historical TNFA entity and its successor Q/C Technologies appear promptly. Investors can also use the platform to track ownership and capital structure changes associated with preferred stock and warrants, and to connect the formal regulatory record with the company’s strategic pivot into quantum-class computing and blockchain infrastructure.
Q/C Technologies, Inc. reported a net loss of $1,242,777 for the three months ended March 31, 2026, reflecting its pre-revenue status as it invests in a new computing-focused business model. Net loss attributable to common stockholders was $1,528,448, or $0.19 per share, compared with $0.36 per share a year earlier.
The company generated no product revenue, with expenses led by general and administrative costs of $1,066,650 and research and development of $510,534. Favorable non-cash items, including a $510,000 gain from changes in derivative liabilities and investment income, reduced the operating loss.
As of March 31, 2026, Q/C Technologies held cash of $1,127,619 and marketable securities of $11,847,305, total assets of $38,291,383, and stockholders’ equity of $20,719,606. Management notes these resources, plus prior capital raises, are expected to fund operations and obligations for at least twelve months. The company has transitioned from pharmaceuticals to energy-efficient blockchain, cryptocurrency infrastructure, and quantum-class laser-based computing based on its exclusive license with LightSolver.
Q/C Technologies, Inc. reported a net loss of $1,242,777 for the three months ended March 31, 2026, reflecting its pre-revenue status as it invests in a new computing-focused business model. Net loss attributable to common stockholders was $1,528,448, or $0.19 per share, compared with $0.36 per share a year earlier.
The company generated no product revenue, with expenses led by general and administrative costs of $1,066,650 and research and development of $510,534. Favorable non-cash items, including a $510,000 gain from changes in derivative liabilities and investment income, reduced the operating loss.
As of March 31, 2026, Q/C Technologies held cash of $1,127,619 and marketable securities of $11,847,305, total assets of $38,291,383, and stockholders’ equity of $20,719,606. Management notes these resources, plus prior capital raises, are expected to fund operations and obligations for at least twelve months. The company has transitioned from pharmaceuticals to energy-efficient blockchain, cryptocurrency infrastructure, and quantum-class laser-based computing based on its exclusive license with LightSolver.
Q/C TECHNOLOGIES, INC. director Chelsea Sierra Voss reported a small open-market purchase of common stock through a Roth IRA. The filing shows an indirect acquisition of 1,753 shares at $3.15 per share, bringing her Roth IRA holdings to 61,555 shares and her separate direct holdings to 239,900 shares.
Q/C TECHNOLOGIES, INC. director Chelsea Sierra Voss reported a small open-market purchase of common stock through a Roth IRA. The filing shows an indirect acquisition of 1,753 shares at $3.15 per share, bringing her Roth IRA holdings to 61,555 shares and her separate direct holdings to 239,900 shares.
Q/C Technologies, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III disclosures on directors, executive compensation, ownership and related-party transactions. The company reports an aggregate market value of non‑affiliate common equity of $3,616,742 on June 30, 2025, based on a $12.28 share price, and 7,853,429 common shares outstanding as of April 27, 2026.
The filing describes an eight‑member board, with a majority meeting Nasdaq independence standards and four standing committees overseeing audit, compensation, nominating/governance, and risk/disclosure. 2025 compensation for named executives includes $392,128 for Chief Medical Officer Mitchell Glass, $166,545 for Interim CFO Ian Rhodes, and $675,220 for Executive Chairman Joshua Silverman, reflecting cash salary plus equity awards such as restricted stock units and options.
The company highlights its 2021 Equity Incentive Plan authorizing 1,400,000 shares, with 1,064,166 shares remaining available as of December 31, 2025. Beneficial ownership data show concentrated holdings by entities such as PharmaCyte Biotech, Inc. and Premas Biotech PVT Ltd. The amendment also discloses several private placements of preferred stock and warrants and consulting agreements with related parties, all subject to the firm’s Code of Business Ethics and Conduct.
Q/C Technologies, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III disclosures on directors, executive compensation, ownership and related-party transactions. The company reports an aggregate market value of non‑affiliate common equity of $3,616,742 on June 30, 2025, based on a $12.28 share price, and 7,853,429 common shares outstanding as of April 27, 2026.
The filing describes an eight‑member board, with a majority meeting Nasdaq independence standards and four standing committees overseeing audit, compensation, nominating/governance, and risk/disclosure. 2025 compensation for named executives includes $392,128 for Chief Medical Officer Mitchell Glass, $166,545 for Interim CFO Ian Rhodes, and $675,220 for Executive Chairman Joshua Silverman, reflecting cash salary plus equity awards such as restricted stock units and options.
The company highlights its 2021 Equity Incentive Plan authorizing 1,400,000 shares, with 1,064,166 shares remaining available as of December 31, 2025. Beneficial ownership data show concentrated holdings by entities such as PharmaCyte Biotech, Inc. and Premas Biotech PVT Ltd. The amendment also discloses several private placements of preferred stock and warrants and consulting agreements with related parties, all subject to the firm’s Code of Business Ethics and Conduct.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.